July 25 (Reuters) - The U.S. Food and Drug
Administration said on Friday it was investigating the death of
an eight-year-old boy who received Sarepta Therapeutics' ( SRPT )
muscular disorder gene therapy Elevidys.
The death occurred on June 7, the agency said.
(Reporting by Mariam Sunny in Bengaluru; Editing by Devika
Syamnath)